氟伏沙明联合阿立哌唑治疗强迫症的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 氟伏沙明联合阿立哌唑治疗强迫症的临床观察
TITLE:
摘要: 目的:观察氟伏沙明联合阿立哌唑治疗强迫症的的疗效和安全性。方法:140例强迫症患者随机分为对照组(70例)和观察组(70例)。两组患者均给予无抽搐性电休克治疗,每周2~3次;在此基础上,对照组患者给予马来酸氟伏沙明片,起始剂量50 mg,口服,每日1次,2周内根据病情改善与患者耐受情况逐渐加量至每日200~300 mg,分 2~3次服用;观察组患者在对照组治疗的基础上给予阿立哌唑片,起始剂量2.5 mg,口服,每日1次,3 d后加量至5 mg,每日1次,2周内根据病情改善与患者耐受情况逐渐加量至每日10~15 mg,分2~3次服用。两组疗程均为8周。观察两组患者的临床疗效,治疗前后耶鲁-布朗强迫症状量表(Y-BCOS)评分、汉密尔顿焦虑量表(HAMA)评分、生存质量综合评定问卷(GQOLI-74)评分及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者Y-BCOS评分、HAMA评分、GQOLI-74评分比较,差异均无统计学意义(P>0.05)。治疗后,两组患者Y-BCOS评分、HAMA评分均显著低于同组治疗前,且观察组显著低于对照组;两组患者GQOLI-74评分均显著高于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗的基础上,氟伏沙明联合阿立哌唑治疗强迫症的疗效显著优于单用氟伏沙明,可有效改善精神症状,提高生活质量,且不增加不良反应的发生。
ABSTRACT: OBJECTIVE: To observe the efficacy and safety of fluvoxamine combined with aripiprazole in the treatment of obsessive-compulsive disorder. METHODS: 140 patients with obsessive-compulsive disorder were randomly divided into control group (70 cases) and observation group (70 cases). All patients received no convulsive electrical shock, 2-3 times a week; based on it, control group was orally given Fluvoxamine tablet with initial dose of 50 mg, once a day, then gradually increased to 200-300 mg/d within 2 weeks based on condition improvement and patients’ tolerance by 2-3 times; observation group was additionally given Aripiprazole tablet 2.5 mg, orally, once a day, and increased to 5 mg after 3 d, once a day, then gradually increased to 10-15 mg/d within 2 weeks based on condition improvement and patients’ tolerance by 2-3 times; all patients were treated for 8 weeks. Clinical efficacy, Yale-Brown obsessive-compulsive symptoms (Y-BCOS) score, Hamilton anxiety (HAMA) score, comprehensive quality of life questionnaire (GQOLI) -74 score before and after treatment, and the incidence of adverse reactions in 2 groups were observed. RESULTS: The total effective rate in observation group was significantly higher than control group, with statistical significance (P<0.05). Before treatment, there were no significant differences in the Y-BCOS score, HAMA score and GQOLI-74 score in 2 groups (P>0.05). After treatment, Y-BCOS score and HAMA score in 2 groups were significantly lower than before, and observation group was lower than control group, GQOLI-74 scores were significantly higher than before, and observation group was higher than control group, with statistical significances (P<0.05). And there was no significant difference in the incidence of adverse reactions (P>0.05). CONCLUSIONS: Based on conventional treatment, fluvoxamine combined with aripiprazole shows better efficacy than fluvoxamine alone in the treatment of obsessive-compulsive disorder, which can effectively improve mental symptoms and the quality of life, does not increase the incidence of adverse reactions.
期刊: 2017年第28卷第3期
作者: 白月辉,梁希江
AUTHORS: BAI Yuehui,LIANG Xijiang
关键字: 氟伏沙明;阿立哌唑;强迫症;疗效;安全性;耶鲁-布郎强迫症状量表
KEYWORDS: Fluvoxamine; Aripiprazole; Obsessive-compulsive disorder; Efficacy; Safety;Yale-Brown obsessive-compulsive symptoms
阅读数: 4272 次
本月下载数: 8 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!